For an investigational treatment being developed for Levodopa-induced Dyskinesia (LID)
Catalent Pharma Solutions has been contracted to manufacture an extended release drug for Parkinson’s disease that is to enter Phase III clinical trials for developer Adamas Pharmaceuticals.
The agreement will see Catalent manufacture ADS-5102 (amantadine HCl) capsules, an investigational treatment being developed for Levodopa-induced Dyskinesia (LID) in patients with Parkinson's disease.
No financial details have been revealed.
Adamas' Chairman and Chief Executive Gregory Went said: 'We believe Catalent’s capabilities make them the right choice to support execution of our upcoming clinical trials.'
Barry Littlejohns, President of Catalent’s Advanced Delivery Technologies business, added: 'Our controlled release formulation expertise and drug delivery technologies will ultimately benefit patients with better treatments.'
If approved, ADS-5102 will be the first medical treatment indicated for patients with LID in Parkinson’s disease.
Adamas Pharmaceuticals, based in Ameryville, CA, US, is currently advancing a pipeline of aminoadamantane-based drug candidates for the treatment of Parkinson’s disease, Alzheimer’s disease, and other CNS disorders.